NCT07806773尚未招募2 期
A Randomized, Open-label, Phase 2a Dose Optimization Study of TUB-040 (a NaPi2b Antibody-drug Conjugate) in Participants With Unresectable or Metastatic Nonsquamous Non-small Cell Lung Cancer
适应症
干预措施
相关药物
试验速览
- 阶段
- 2 期
- 状态
- 尚未招募
- 发起方
- Tubulis GmbH
- 入组人数
- 80
- 试验地点
- 2
- 主要终点
- Percentage of Participants Experiencing Treatment-Emergent Adverse Events (TEAEs)
研究概览
简要总结
The goal of this clinical study is to learn more about the study drug TUB-040, safety, tolerability, pharmacokinetics (PK), and effectiveness in treating patients with unresectable or metastatic non-small cell lung cancer (NSCLC).
The primary objectives of this study are to determine the safety and tolerability and effectiveness of TUB-040, and/or recommended Phase 2 dose (RP2D).
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 干预模型
- Parallel
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 18 Years 至 —（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Adults, male or nonpregnant, nonbreastfeeding female, age ≥18 years at the date of consent.
- •Eastern Cooperative Oncology Group performance status of 0 or
- •Documented radiographic progression on or after the most recent line of anticancer therapy.
- •Life expectancy of more than 12 weeks for disease-related mortality as evaluated by the INV.
- •At least 1 radiologically measurable lesion by RECIST v1.1, which can include a lesion in an irradiated field that shows progression according to RECIST v1.
- •Stable metastases to the central nervous system (CNS) are eligible only after definitive therapy (such as surgery, radiotherapy, stereotactic therapy) was provided and the individual is asymptomatic and off systemic steroids and anticonvulsants. Individuals with treated brain metastases that are no longer symptomatic may be included if they have recovered from the acute toxic effects of radiotherapy. A minimum of 7 days for targeted radiation and 14 days for whole brain radiation must have elapsed prior to Cycle 1 Day
- •Adequate hematologic function as indicated by:
- •Platelet count ≥ 100,000/mm3 (no platelet transfusion or growth factors, eg, eltrombopag, romiplostim, or interleukin-11 within 4 weeks before the first dose of study treatment)
- •Hemoglobin ≥ 9.0 g/dL (no packed red blood cell transfusion or growth factors [eg, erythropoietin, darbepoetin] within 4 weeks before the first dose of study treatment and/or long-acting white blood cell growth factors within 28 days before first dose of study treatment)
- •Absolute neutrophil count ≥ 1500/μL (no growth factors [eg, granulocyte colony stimulating factor, granulocyte macrophage-colony stimulating factor] within 4 weeks before the first dose of study treatment)
- •International normalized ratio (INR) ≤ 1.5 and activated partial thromboplastin time ≤ 1.5 × upper limit of normal (ULN) in the absence of anticoagulation therapy. If individuals are on anticoagulation therapy with a specific INR goal, INR should be within the therapeutic range for the medical indication
- •Adequate hepatic function as defined by a total bilirubin level ≤ 1.5 × ULN, aspartate aminotransferase (AST) level ≤ 2.5 × ULN, and alanine aminotransferase (ALT) level ≤ 2.5 × ULN.
- •For documented Gilbert's syndrome, a total bilirubin < 3 × ULN is acceptable
- •For individuals with liver metastases, AST and ALT < 5 × ULN is acceptable
- •Alkaline phosphatase (ALP) < 2.5 × ULN, except if there is an alternative explanation for ALP elevation other than hepatic failure, such as the presence of bone metastases.
- •Adequate renal function defined by glomerular filtration rate (GFR) ≥ 50 mL/min (according to the Chronic Kidney Disease Epidemiology Collaboration formula).
- •Resolution of all adverse events (AEs) from prior therapy or surgical procedures to Grade ≤ 1 or to baseline (exceptions included alopecia, hyperpigmentation or discoloration of the skin and nails [including vitiligo], stable immune-related toxicity such as hypothyroidism for individuals on hormone replacement or corticosteroid treatment with prednisone, or equivalent, of ≤ 10 mg daily, and Grade 2 peripheral sensory neuropathy after prior treatment with taxane or other anticancer therapy).
- •Completed washout of prior therapy:
- •Systemic anticancer therapy within 5 half-lives or 4 weeks, whichever is shorter, prior to first dose of study treatment. Hormonal therapy is not considered anticancer therapy.
- •Radiotherapy ≥ 2 weeks prior to the first dose of study treatment
- •Willing to undergo a noncontrast high-resolution computed tomography scan of the chest and pulmonary function tests at screening.
- •Individuals with history of hepatitis C virus (HCV) infection are eligible if HCV viral load is undetectable at screening and they have completed curative antiviral therapy at least 4 weeks before enrollment.
- •Women of childbearing potential (WOCP) must have a negative serum pregnancy test during screening and be neither breastfeeding or intending to become pregnant during study participation. A female will be considered to be of childbearing potential unless they have undergone permanent sterilization (ie, hysterectomy, bilateral salpingectomy or bilateral oophorectomy) or are postmenopausal.
- •For WOCP, agreement must be provided to use a medically approved, highly effective contraceptive method from the time of screening throughout the study and for 6 months after the last administration of study treatment.
- •Ability to understand, give written informed consent, comply with all study-related procedures, medication use, and assessments
- •No history of noncompliance with medical regimens or considered, in the opinion of the INV, to be potentially unreliable and/or uncooperative.
排除标准
- •Mixed histology NSCLC (eg, small cell lung cancer/NSCLC) or histology other than adenocarcinoma
- •Prior pneumonectomy
- •Newly identified or known unstable brain metastases, spinal cord compression, active CNS disease, progressive multifocal leukoencephalopathy, and/or carcinomatous meningitis.
- •Pregnant, lactating, or breastfeeding.
- •History of hypersensitivity to exatecan or excipients of the TUB-040 formulation.
- •Prior treatment with an ADC-containing topoisomerase 1 (Topo-1) inhibitor payload (or other camptothecin derivatives) or any ADC targeting NaPi2b. ADCs with other payloads are allowed (eg, monomethyl auristatin E, monomethyl auristatin F, etc.).
- •Discontinuation of the most recent systemic anticancer therapy due to hematologic toxicity.
- •Concomitant use of strong inhibitors or strong inducers of cytochrome P450 3A
- •Participation in any interventional clinical studies either concurrently or within 28 days or 5 half-lives (whichever is shorter) prior to enrollment of any investigational pharmacologic agent, imaging materials, including dyes, investigational surgical techniques, or devices.
- •Radiotherapy < 2 weeks prior to start of study treatment (planned C1D1), except in the case of stereotactic radiation to the brain, in which case the required interval is 7 days.
- •Major surgery within 21 days prior to signing ICF.
- •Active interstitial lung disease (ILD)/pneumonitis or history of noninfectious ILD/pneumonitis/radiation pneumonitis requiring steroid treatment.
- •Resting Fridericia's corrected QT interval (QTcF) > 470 msec. If a single QTcF is > 470 msec, the patient may enroll if the mean QTcF from 3 electrocardiograms (ECG) is < 470 msec.
- •History of nephrotic syndrome or proteinuria Grade ≥
- •Active keratitis or corneal disorder or history of corneal disease including history of herpes simplex virus keratitis within 4 months prior to enrollment.
- •Active, uncontrolled, or severe impairment of the urogenital, renal, hepatobiliary, cardiovascular, respiratory, gastrointestinal, neurologic, or hematopoietic systems which, in the opinion of the INV, would predispose the individual to the development of complications from the administration of protocol therapy.
- •Documented concurrent nonmalignant comorbidities such as unstable or uncontrolled pectoral angina, myocardial infarction during the last 6 months, valvular heart disease that requires treatment, acute myocarditis, or unstable or worsening congestive heart failure (New York Heart Association III or IV).
- •Any concurrent anticancer chemotherapy, radiotherapy (palliative radiation may be permitted after approval by the sponsor), hormonal therapy, immunotherapy, biologic, or corticosteroid therapy.
- •Live attenuated vaccines within 30 days prior to study enrollment.
- •Positive for hepatitis B surface antigen or hepatitis B DNA.
- •Acute, chronic, or severe recurrent infections (per INV's judgment) of active bacterial, viral, fungal, mycobacterial, or other infection of ≤ 14 days after systemic anti-infective treatment prior to randomization.
- •Note: Other protocol defined Inclusion/Exclusion criteria may apply.
研究组 & 干预措施
NSCLC Dose 1
Experimental
Participants will receive TUB-040 administered as an intravenous (IV) infusion on Day 1 of each treatment cycle. Until disease progression, unacceptable toxicity, or withdrawal of consent.
干预措施: TUB-040 (Drug)
NSCLC Dose 2
Experimental
Participants will receive TUB-040 administered as an IV infusion on Day 1 of each treatment cycle. Until disease progression, unacceptable toxicity, or withdrawal of consent.
干预措施: TUB-040 (Drug)
结局指标
主要结局
Percentage of Participants Experiencing Treatment-Emergent Adverse Events (TEAEs)
时间窗: From enrollment until 30 days after last dose of study drug
Incidence and severity of treatment-emergent adverse events (TEAEs)
Overall Response Rate (ORR)
时间窗: Enrollment until approximately 80 days since last dose of study drug
Assessment of overall response rate (ORR) by Response Evaluation Criteria for Solid Tumors (RECIST) v1.1 as assessed by the investigator (INV)
次要结局
- Duration of response (DoR)(Up to approximately 24 months)
- Disease control rate (DCR)(Up to approximately 24 months)
- Progression-free survival (PFS)(Up to approximately 24 months)
- Overall survival (OS)(Up to approximately 24 months)
- Pharmacokinetic (PK) Parameter: Cmax of TUB-040(Up to approximately 24 months)
- Pharmacokinetic (PK) Parameter: Tmax(Up to approximately 24 months)
- Pharmacokinetic (PK) Parameter: AUC(Up to approximately 24 months)
- Pharmacokinetic (PK) Parameter: t1/2(Up to 3 yeaUp to approximately 24 months)
- Percentage of Participants Who Develop Anti-TUB-040 Antibodies(Up to approximately 24 months)
研究者
研究点 (2)
Loading locations...
相似试验
尚未招募
1 期
Study of TUB-040 in Patients With Recurrent or Progressive Uterine Cancer After Chemotherapy and Immune TherapyUterine Endometrial CancerNCT07743541Tubulis GmbH100
招募中
2 期
A Study Testing a New Targeted Drug (TUB-040) in combination with Standard Chemotherapy for Women with Ovarian Cancer2025-524691-33-00Tubulis GmbH42
招募中
2 期
A Dose Optimization/Expansion Study of SAR445877 in Adult Chinese Participants With Advanced Gastric or Gastroesophageal Junction CancerOesophageal CarcinomaGastric CancerNCT07692204Sanofi30
尚未招募
2 期
Clinical Trial Evaluating the Efficacy and Safety of TQB3454 Tablets in Participants With Advanced Solid TumorsAdvanced Solid TumorsNCT07738679Chia Tai Tianqing Pharmaceutical Group Co., Ltd.127
招募中
2 期
Phase II Study of JS212/JS213 as Monotherapy and in Combination in Patients With Advanced Malignant Solid TumorsNCT07480733Shanghai Junshi Bioscience Co., Ltd.410